Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
drug-eluting stent
in-stent restenosis
mortality
occlusion
peripheral artery disease
target lesion revascularization
Journal
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
ISSN: 1545-1550
Titre abrégé: J Endovasc Ther
Pays: United States
ID NLM: 100896915
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
pubmed:
22
10
2020
medline:
25
6
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
To present a subgroup analysis of patients from a large real-world study evaluating the safety and effectiveness of the Zilver PTX drug-eluting stent (DES) for treating femoropopliteal in-stent restenosis (ISR). This study examined patients enrolled in the Zilver PTX Japan Post-Market Surveillance Study ( No device-related or procedure-related deaths or paclitaxel-related adverse events were reported. All-cause mortality was 25.1% at 5 years. Stent fracture was observed in 5 stents through 5 years. The 5-year rate of freedom from clinically-driven TLR was 73.4%, and the rate of clinical benefit was 63.6%. Improvement in Rutherford category and ankle-brachial index was sustained through 5 years. The safety and effectiveness of the Zilver PTX stent for the treatment of femoropopliteal ISR lesions demonstrated that this device provides a favorable treatment option in this difficult-to-treat subgroup.
Identifiants
pubmed: 33084502
doi: 10.1177/1526602820966708
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Banques de données
ClinicalTrials.gov
['NCT02254837']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM